Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
|
|
Xencor Inc (XNCR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2015 |
8-K
| Quarterly results, Conference call transcript|
Docs:
|
"Xencor Reports Second Quarter 2015 Financial and Operating Results MONROVIA, Calif. — August 4, 2015 — Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the second quarter ended June 30, 2015 and provided a review of its business highlights. “Currently eight XmAb® antibody candidates are in clinical testing, six with partners and two internal. The accelerating momentum of this pipeline of antibodies is a direct result of the breadth of immune biology that our proprietary XmAb platform addresses. We recently unveiled updates on our development plans for our internally-led programs XmAb®5871 in the rare autoimmune disorde...",
"Q2 2015 Xencor, Inc. Earnings Conference Call Transcript" |
|
| 05/16/2014 |
8-K
| Quarterly results, Conference call transcript |
|
|